With a decades-long commitment to psychedelic advocacy and research, a firsthand knowledge of the life-changing benefits of plant medicine, and his role as CEO of Psygen Labs, Danny Motyka brings a unique perspective to the future of psychedelics. In this episode, he and Paul discuss the differences between the cannabis and psychedelic industries, the role of plant medicines as preventative treatments, and what psychedelic therapy might look like in the near future.